Broome Oncology

Neuroblastoma News

SWOG Launches National Immunotherapy Clinical Trial for Rare Cancers (March 23, 2017)

People with rare cancers now have the option of joining a national clinical trial testing leading-edge immunotherapies for a wide variety of tumor types. It’s the first federally funded immunotherapy trial devoted to rare cancers. Despite their name,... Continue Reading

Unituxin® Approved for Treatment of Children with High-Risk Neuroblastoma (April 9, 2015)

The U.S. Food and Drug Administration (FDA) has announced the first-ever drug approval for the treatment of children with high-risk neuroblastoma. In clinical trials Unituxin® (dinutuximab) has improved survival among children with this type of cancer... Continue Reading

End-of-Life Care Remains Aggressive, Despite Patient Wishes (September 16, 2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive... Continue Reading

Cancer Deaths on the Decline (February 11, 2013)

Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National Cancer Institute. What’s more—cancer incidence... Continue Reading

Targeted Agent Xalkori May Benefit Children with Anaplastic Lymphoma (May 23, 2012)

The targeted agent Xalkori® (crizotinib) appears to drastically reduce the size of tumors in children with refractory anaplastic large cell lymphoma, according to the results of a phase I study that will be presented at the annual meeting of the American... Continue Reading

Approximately 16% of Worldwide Cancers Caused By Preventable Infections (May 17, 2012)

Two million cancer cases each year—or roughly 16 percent of cancers worldwide—are the result of preventable and treatable infections such as human papillomavirus (HPV) and Hepatitis C (HCV), according to the results of a study published in The Lancet... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

Hycamtin/Cyclophosphamide Delays Progression of Recurrent Neuroblastoma (September 13, 2010)

Children with recurrent or refractory neuroblastoma experienced an improvement in progression-free survival when treated with the combination of Hycamtin® (topotecan) plus cyclophosphamide; overall survival, however, was not improved compared with Hycamtin... Continue Reading

Neuroblastoma Survival has Improved (May 12, 2010)

Between 1979 and 2005, ten-year overall survival with neuroblastoma improved from 34.9% to 65%. The results of this study, conducted in Italy, were published in the Journal of Clinical Oncology. Neuroblastoma is a disease in which cancerous cells form... Continue Reading

Latest Neuroblastoma News By Stage


General Neuroblastoma

Targeted Agent Xalkori May Benefit Children with Anaplastic Lymphoma (May 23, 2012)

The targeted agent Xalkori® (crizotinib) appears to drastically reduce the size of tumors in children with refractory anaplastic large cell lymphoma, according to the results of a phase I study that will be presented at the annual meeting of the American... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (March 26, 2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

Hycamtin/Cyclophosphamide Delays Progression of Recurrent Neuroblastoma (September 13, 2010)

Children with recurrent or refractory neuroblastoma experienced an improvement in progression-free survival when treated with the combination of Hycamtin® (topotecan) plus cyclophosphamide; overall survival, however, was not improved compared with Hycamtin... Continue Reading

Neuroblastoma Survival has Improved (May 12, 2010)

Between 1979 and 2005, ten-year overall survival with neuroblastoma improved from 34.9% to 65%. The results of this study, conducted in Italy, were published in the Journal of Clinical Oncology. Neuroblastoma is a disease in which cancerous cells form... Continue Reading

More General Neuroblastoma